Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.56 |
| ▸ | CSF1R | P07333 | 2/20 | 0.43 |
| ▸ | HAT1 | O14929 | 2/20 | 0.42 |
| ▸ | EP300 | Q09472 | 2/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.42 |
| ▸ | GSK3B | P49841 | 4/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | NEK2 | P51955 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19902522 | 0.91 | USP30 (0.46) | USP30CSF1RHAT1EP300ROCK1 | |
| SCHEMBL19902637 | 0.91 | USP30 (0.46) | USP30CSF1RHAT1EP300ROCK1 | |
| SCHEMBL19902392 | 0.90 | ROCK1 (0.43) | USP30CSF1RROCK1DYRK1AROCK2 | |
| SCHEMBL17452958 | 0.90 | ROCK2 (0.53) | USP30CSF1RHAT1EP300ROCK1 | |
| SCHEMBL19902368 | 0.88 | ROCK1 (0.49) | USP30CSF1RROCK1ROCK2 | |
| SCHEMBL19902485 | 0.88 | ROCK1 (0.47) | USP30ROCK1GSK3BDYRK1AROCK2 | |
| SCHEMBL19902532 | 0.87 | DYRK1A (0.46) | USP30ROCK1DYRK1AROCK2 | |
| SCHEMBL17452960 | 0.86 | ROCK2 (0.54) | USP30CSF1RHAT1EP300ROCK1 | |
| SCHEMBL19902648 | 0.85 | ROCK1 (0.43) | USP30CSF1RROCK1ROCK2 | |
| SCHEMBL20229984 | 0.85 | ROCK1 (0.42) | USP30CSF1RROCK1GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | USP30 3527/4885CSF1R 2895/4885HAT1 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.